ABSTRACT
INTRODUCTION
. Whilst the majority of patients achieve an undetectable HIV RNA level on these treatments, high levels of adherence are required for successful treatment outcomes; recent clinical trials show significantly worse outcomes amongst sub-optimally adherent individuals (defined as adherence \95%) on NNRTI-and PI-based first-line regimens [2, 3] . Side effects remain the commonest reason for switching antiretroviral therapy [4, 5] , and side effects are a common reason for late and missed doses [6] . Several agents [e.g. lamivudine, emtricitabine (FTC), efavirenz (EFV), nevirapine and raltegravir (RTG)] have a low genetic barrier to resistance and may be rendered ineffective by single nucleotide substitutions in the viral genome [7] [8] [9] , while others [e.g. rilpivirine (RPV) and abacavir (ABC)] may have limited potency at high HIV viral load, are best avoided in patients with chronic kidney disease [e.g. tenofovir (TDF), atazanavir (ATV)], or in those at high risk of coronary heart disease (ABC), or should not be used in HLA B5701-positive patients (ABC) [1] . While many patients prefer a once-daily regimen consisting of a small number of tablets, some agents (e.g. RTG) require twice-daily dosing. This inhibitory effect on P-glycoprotein and CYP3A4 is achieved at low, sub-therapeutic doses (100-200 mg daily) that are generally better tolerated [12] .
DRAWBACKS OF PHARMACOENHANCEMENT
Inhibition of CYP3A4 (and other CYP isoenzymes) will affect concurrently administered medications metabolised by this pathway. COBI interactions are less widely studied than RTV; while data are awaited it may be necessary to draw on the experience with RTV when predicting likely COBI interactions. Some drugs cannot be co-administered with CYP3A4 inhibitors due to significant increases in concentrations of the co-administered agent (e.g. fluticasone, simvastatin) while others require dose adjustment (e.g. rifabutin, for which interaction data with RTV and COBI is available, and clarithromycin, for which only the interaction with RTV has been studiedadvice for COBI is extrapolated from this). In addition, neither RTV nor COBI is 'clean' in terms of CYP inhibition; the impact of both on hepatic enzymes is more complex than CYP3A4 inhibition alone (Table 1 ) [10] , further increasing the potential for important drugdrug interactions. The low doses of ritonavir used for boosting may still be associated with tolerability and toxicity issues [13, 14] . There is a paucity of data regarding the tolerability of COBI as a single agent but when used to boost ATV, adverse events and tolerability were similar for COBI and RTV [15] . [24] . Neither COBI nor EVG requires dose modification in patients with severe renal impairment (creatinine clearance \30 mL/min) [25] or moderate liver disease (Child-PughTurcotte class B) [26] . However, the median EFV C tau remained above the IC 90 of wild-type HIV for at least 4 weeks and, by the end of the first week, the median EVG C tau was threefold higher than the IC 95 ,
suggesting that EFV activity is maintained while EVG concentrations reach therapeutic concentrations [27] . A phase IIIb study is evaluating the safety of a regimen switch from Atripla to Stribild in terms of continued viral suppression.
COBICISTAT AND DRUG-DRUG INTERACTIONS
Due to its inhibition of CYP enzymes, it is anticipated that COBI exposure will result in drug-drug interactions similar to those seen with RTV (see above). However, few studies have examined the effects of COBI on the plasma concentrations of other drugs and until the results of such studies emerge, it would appear prudent to avoid COBI in patients who require drugs with a narrow therapeutic index (e.g. cancer chemotherapy, Further and up-to-date information is available on the HIV Drug Interactions webpage [28] .
COBICISTAT-CONTAINING HIV THERAPY: RESULTS FROM THE PHASE III CLINICAL TRIALS PROGRAMME
The results of three studies have been presented to date; two studies investigated the efficacy and safety of Stribild [29] [30] [31] [32] , while the third study compared COBI with RTV, each coadministered with ATV and TDF/FTC [33] .
The GS-US-236-0102 and 0103 studies are ongoing phase III, double-blind, randomised, placebo-controlled trials of antiretroviral-naïve HIV-1-positive adults [31, 32] 
RENAL SAFETY
As described above, COBI inhibits the renal creatinine transporter MATE1. Although creatinine is freely filtered at the glomerulus, some 10-15% is actively secreted in the proximal tubule. Abrogation of tubular creatinine secretion results in mild increases in serum creatinine concentrations and mild reductions in estimated creatinine clearance.
In healthy volunteers, COBI exposure resulted in reduced creatinine clearance (as measured with the Cockcroft-Gault formula) with minimal change in the actual (iohexolmeasured) glomerular filtration rate (-9.9 vs.
-2.7 mL/min in those with creatinine clearance Adverse events, including bilirubin elevations, jaundice, nausea and diarrhoea, occurred with equal frequency in both arms COBI-containing regimen non-inferior to the RTV-containing regimen Consistent rates of viral suppression were observed across CD4 cell count and baseline HIV RNA strata ATV atazanavir, COBI cobicistat, FTC emtricitabine, II integrase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside/ nucleotide reverse transcriptase inhibitor, PI protease inhibitor, RTV ritonavir, TDF tenofovir disoproxil fumarate C80 mL/min, and -11.9 vs. -3.6 mL/min in those with creatinine clearance 50-79 mL/min) [35] . Baseline creatinine clearance (range 50-140 mL/min) did not affect the magnitude of the reduction in creatinine clearance with COBI exposure [35] . In the 0102 and 0103 studies, serum creatinine levels in the Stribild arm increased by approximately 10-15% in the first 4 weeks, and creatinine clearance declined by 10-15 mL/min [29, 30] . However, at 4 weeks a new ''set point'' was reached, with minimal subsequent change up to week 96 (-2.6 vs.
-1.0 mL/min for Stribild and Atripla in the 0102 study, -1.8 vs. -4.4 mL/min for Stribild and TDF/FTC/ATV/RTV in the 0103 study) [18, 19] . In the 0114 study, patients in the COBI arm experienced greater reductions in creatinine clearance (-13 vs. -9 mL/min) than in the RTV arm [33] .
Five patients (1.4%) in the 0102 study, all in the Stribild arm, had renal events (reported as elevated serum creatinine in two, renal failure in two, Fanconi syndrome in one; a total of four patients had evidence of proximal tubulopathy that led to study drug discontinuation before week 48) [29] . Further two patients (0.6%) in the Stribild arm discontinued study drug between weeks 48 and 96, because of renal adverse events consisting of serum creatinine elevations not accompanied by proximal tubulopathy [31] . In the 0103 study, five patients (Stribild arm 3, ATV/RTV arm 2) discontinued study drug due to renal events before week 96; none had evidence of proximal tubulopathy [32] . In the 0114 study, 1.7% and 1.4% of patients discontinued study medication for renal events in the COBI and RTV arms, and 5 vs. 2 cases had proximal tubulopathy [33] .
The low rate of renal discontinuations and renal tubular disease suggests an overall favourable renal safety profile of Stribild and COBI. Indeed, data from patients with creatinine clearance 50-89 mL/min who initiated Stribild or substituted RTV with COBI observed no increased rate of renal toxicity or renal discontinuations [36] . The increases in serum creatinine concentration and the reductions in estimates of creatinine clearance and glomerular filtration rate are unlikely to be of clinical importance. Some of the renal discontinuations were likely to be due to patients meeting prespecified criteria for discontinuation rather than secondary to overt renal toxicity. Nonetheless, the population included in the clinical trials was at low risk of kidney injury and despite this a small number developed significant renal tubular disease requiring drug discontinuation. The risk factors for TDF-induced Fanconi syndrome and renal tubular disease remain poorly defined but may point to an interaction between COBI and tenofovir at renal tubular level, as previously suggested for RTV [37] . Although such an interaction is not predicted by in vitro studies (Fig. 1 ), clinicians will need to remain alert to the nephrotoxic potential of Stribild in clinical practice. 
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